ClinicalTrials.Veeva
Menu

Find clinical trials for Non-Hodgkin Lymphoma in Cleveland, OH

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Lymphoma
B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma
Follicular Lymphoma
Recurrence
B-Cell Chronic Lymphocytic Leukemia
Mantle-Cell Lymphoma

Non-Hodgkin Lymphoma trials near Cleveland, OH, USA:

Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Non-Hodgkin Lymphoma

-T treatment.This phase 1 study will evaluate safe dose and provide initial signal of the activity of BAFF CAR-T cells against relapsed non- ...

Enrolling
Lymphoma, Non-Hodgkin Lymphoma, B-Cell
Drug: BAFF CAR-T

Phase 1

Luminary Therapeutics

Cleveland, Ohio, United States and 1 other location

medical needs, such as Human Immunodeficiency Virus (HIV)-associated lymphoma, primary and secondary central nervous system (CNS) lymphoma...

Enrolling
Lymphoma, Non-Hodgkins
Refractory B-Cell Non-Hodgkin Lymphoma
Biological: EB103

Phase 1, Phase 2

Estrella Immunopharma, Inc.

Cleveland, Ohio, United States and 4 other locations

ARV-393 in patients diagnosed with advanced Relapsed/Refractory non-Hodgkin's lymphoma (R/R NHL) to determine if ARV-393 m-...

Enrolling
Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL)
Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL)
Drug: ARV-393
Drug: Glofitamab

Phase 1

Arvinas
Arvinas

Cleveland, Ohio, United States and 20 other locations

The primary objective of this study is to characterize the safety and tolerability of loncastuximab tesirine in combination with polatuzumab vedotin,...

Active, not recruiting
Refractory B-Cell Non-Hodgkin Lymphoma
Relapsed B-Cell Non-Hodgkin Lymphoma
Drug: Loncastuximab Tesirine
Drug: Polatuzumab Vedotin

Phase 1

ADC Therapeutics

Cleveland, Ohio, United States and 39 other locations

safety and efficacy of AZD4512 monotherapy or in combination with other anticancer agent(s), in participants with Relapsed/Refractory B-cell Non...

Enrolling
B-cell Non-Hodgkin Lymphoma
Drug: AZD4512

Phase 1, Phase 2

AstraZeneca
AstraZeneca

Cleveland, Ohio, United States and 22 other locations

This is a global Phase 2, open-label, single-arm, multicohort, multicenter study to evaluate efficacy and safety of JCAR017 in adult subjects with r/...

Active, not recruiting
Lymphoma, Non-Hodgkin
Drug: Fludarabine
Drug: JCAR017

Phase 2

Celgene
Celgene

Cleveland, Ohio, United States and 48 other locations

This research study is for people who have relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL) that has not respond-...

Enrolling
Primary Mediastinal Large B Cell Lymphoma
Marginal Zone Lymphoma
Drug: Fludarabine/cyclophosphamide
Drug: Tafasitamab

Phase 1

Paolo Caimi, MD

Cleveland, Ohio, United States and 1 other location

of adult participants with relapsed or refractory (r/r) B-Cell non-Hodgkin lymphoma (B-NHL) or frontline high-risk diffuse...

Active, not recruiting
Lymphoma, B-Cell
Lymphoma, Large B-Cell, Diffuse
Biological: JNJ-90014496

Phase 1, Phase 2

Janssen (J&J Innovative Medicine)
Janssen (J&J Innovative Medicine)

Cleveland, Ohio, United States and 31 other locations

Locations recently updated

Researchers are looking for new ways to treat 2 types of non-Hodgkin lymphoma (NHL) called follicular lymphoma (F...

Enrolling
Lymphoma, Follicular
Lymphoma, Large B-Cell, Diffuse
Biological: MK-1045

Phase 1, Phase 2

Merck Sharp & Dohme (MSD)
Merck Sharp & Dohme (MSD)

Cleveland, Ohio, United States and 45 other locations

The goal of this multicenter study is to test JNJ-90009530 in Relapsed or Refractory Non-Hodgkin Lymphoma Patients. The ma...

Active, not recruiting
Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
Drug: JNJ-90009530

Phase 1

Janssen (J&J Innovative Medicine)
Janssen (J&J Innovative Medicine)

Cleveland, Ohio, United States and 14 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems